Peter Voorhees, MD

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.

Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

Peter Voorhees, MD, associate professor, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the triplet regimen of pomalidomide, dexamethasone, and ixazomib in patients with double refractory multiple myeloma.

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.